Objectives:
1. Recognize the differences in natural history of Alport syndrome by sex and genotype
2. Formulate a treatment plan for patients with Alport syndrome
3. Discuss the ongoing design and challenges in clinical trials in Alport syndrome

Michelle Rheault is a pediatric nephrologist and director of the Division of Pediatric Nephrology at the University of Minnesota Masonic Children's Hospital. Her interest in Alport syndrome started during her fellowship training when she helped to characterize the first mouse model of Xlinked Alport syndrome. From there, she turned her attention to clinical research and is currently codirector of the Alport Syndrome Treatment and Outcomes Registry (ASTOR) and an investigator in clinical trials of new therapies for patients with Alport syndrome. She has a special interest in women with Alport syndrome. Dr. Rheault has written a number of book chapters, reviews, and original science articles about Alport syndrome. In addition, she is on the steering committee for the Pediatric Nephrology Research Consortium and a member of the American Board of Pediatrics Subboard of Pediatric Nephrology.